This site is intended for U.S. healthcare professionals.

Translating mRNA
Educational Webinar Series

The Pfizer Vaccines US Medical Affairs Team invites you to attend an educational webinar series titled Translating mRNA which is focused on providing education on COVID-19 and vaccination. The webinar series is designed to communicate scientific information which may include recent study results to inform healthcare providers  regarding Pfizer and BioNTech’s COVID-19 vaccines.

The webinar series will include a live question-and-answer session with Pfizer medical experts.

We will soon be hosting a Translating mRNA session.

If you would like to be notified when the registration opens for the next webinar click here

To view recordings of previous Translating mRNA webinars and other medical resources click here or here.

Intended Audience: US healthcare professionals including but not limited to physicians, nurse practitioners, pharmacists, and physician assistants.

Continuing medical education credit is NOT associated with this event.

Indication:
COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.

Emergency Use Authorization:
Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula) has not been approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 6 months through 11 years of age. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b) (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.​

For most recent US Full Prescribing Information and Fact Sheets, please visit   www.cvdvaccine-us.com